K. Lea Sewell - Concepedia

Author

K. Lea Sewell

Also Known As

K L Sewell, K Lea Sewell, K Sewell, K. L. Sewell, K. Lea Sewell, K. Sewell, K.L Sewell, K.L. Sewell, K.Lea Sewell, Kathryn L. Sewell

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Beth Israel Deaconess Medical Center Harvard University Ionis Pharmaceuticals (United States)Pfizer (United States)Schlosspark-Klinik

About

K. Lea Sewell is an author at Beth Israel Deaconess Medical Center specializing in medicine, rheumatology, and psoriatic arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	695
2	Health Sciences	1	1	27
3	Allergy	1	1	630
4	Gastroenterology	1	1	25
5	Geriatrics	1	1	13

K. Lea Sewell

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Effects of Oral Administration of Type II Collagen on Rheumatoid Arthritis David E. Trentham, Roselynn Dynesius‐Trentham, E. John Orav, Science ImmunologyType Ii CollagenOral AdministrationDermatologyImmunotherapy	1993	630
Risedronate therapy prevents corticosteroid-induced bone loss : A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Stanley Cohen, Robert M. Levy, Michael Keller, Arthritis & Rheumatism	1999	615
Phase 1 Study of Anti-CTGF Monoclonal Antibody in Patients with Diabetes and Microalbuminuria Sharon G. Adler, Sherwyn Schwartz, Mark E. Williams, Clinical Journal of the American Society of Nephrology	2010	197
Phase I Trial of ISIS 104838, a 2′-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-α K. Lea Sewell, Richard S. Geary, Brenda F. Baker, Journal of Pharmacology and Experimental Therapeutics	2002	120
Suppression of collagen‐induced arthritis through adenovirus‐mediated transfer of a modified tumor necrosis factor α receptor gene Christine Le, A. Graham Nicolson, Alejandro Morales, Arthritis & Rheumatism	1997	101
Dose ranging pharmacokinetic trial of high‐dose alicaforsen (intercellular adhesion molecule‐1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease Bruce Yacyshyn, Charles F. Barish, J S Goff, Alimentary Pharmacology & Therapeutics	2002	70
Interleukin‐2 diphtheria fusion protein (dab<sub>486</sub>il‐2) in refractory rheumatoid arthritis a double‐blind, placebo‐controlled trial with open‐label extension Larry W. Moreland, K. Lea Sewell, David E. Trentham, Arthritis & Rheumatism	1995	63
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy Stanley Cohen, Rieke Alten, Hideto Kameda, Arthritis Research & Therapy	2018	58
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis Roy Fleischmann, Rieke Alten, Margarita Pileckytė, Arthritis Research & Therapy	2018	52
DAB<sub>486</sub>IL‐2 fusion toxin in refractory rheumatoid arthritis K. Lea Sewell, Karen Parker, Thasia Woodworth, Arthritis & Rheumatism	1993	51

Page 1